View Archive

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Merck & Co., Inc.

ASCO GI: Exploitation of the DNA Damage Response and the Emerging Role of PARP Inhibition in Pancreatic Cancer

ASCO GI: Exploitation of the DNA Damage Response and the Emerging Role of PARP Inhibition in Pancreatic Cancer

Friday, January 24, 2020

Dinner and Registration: 6:00 pm – 7:00 pm
Scientific Session: 7:00 pm – 9:00 pm

San Francisco Marriott Marquis
Dinner and Program: Yerba Buena Ballroom, Salon 7, Lower B2 Level
780 Mission Street, San Francisco, CA 94103
Phone: (415) 896-1600

DNA Damage Response and PARP Inhibition in Pancreatic Cancer: Program Overview

PARP inhibitors target alterations in genes associated with the DNA damage response (DDR). Actionable alterations in DDR-associated genes (BRCA1/2 or ATM) are commonly present in pancreatic cancer, and multiple PARP inhibitors are in clinical development for these patients. Clinicians need to be aware of the mechanism of PARP inhibition, and the possible application of PARP inhibitors in the treatment of susceptible pancreatic tumors. The clinical decision making process should be supported by evidence-based rationales when deciding which patients will benefit from new PARP-targeted treatment approaches, while minimizing adverse events as appropriate.

This satellite symposium at the 2020 Gastrointestinal Cancers Symposium will feature a series of case-based panel discussions given by experts in pancreatic cancer who will discuss mutations associated with deficiencies in the DDR; recommendations for testing to detect molecular aberrations; and the incorporation of DDR-targeting agents into treatment regimens as clinical trial data matures and agents are reviewed by the FDA.

Benefits of Attending This Pancreatic Cancer CME Symposium Hosted by PER®

  • Utilize insights from leading clinical experts to appropriately test for actionable DDR-associated mutations in patients with pancreatic cancer
  • Acquire knowledge from several experts in pancreatic cancer simultaneously via case-based panel discussions
  • Discuss challenging clinical cases with colleagues and leaders in clinical research for pancreatic cancer
  • Navigate the changing treatment paradigm for targeted therapy in pancreatic cancer with evidence-based reasoning
  • Network with clinicians who have experience with PARP-targeted therapy for pancreatic cancer

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Merck & Co., Inc.

Target Audience: HCPs Who Treat Pancreatic Cancer

This educational program is directed toward all attendees of the 2020 Gastrointestinal Cancers Symposium, including medical oncologists, surgical oncologists, radiation oncologists, hepatologists, pathologists, and gastroenterologists interested in the treatment of pancreatic cancer. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with pancreatic cancer will be invited to participate.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the mechanistic rationale for targeting DDR in the treatment of patients with pancreatic cancer
  • Outline evidence pertaining to biomarker studies that may guide the use of PARP inhibition in pancreatic cancer
  • Examine efficacy and safety results concerning trials that have evaluated PARP inhibition and other DDR-targeting strategies for patients with pancreatic cancer
  • Appraise the role of PARP inhibition strategies in the context of combination regimens and sequencing paradigms in pancreatic cancer management

Program Chair

Eileen M. O’Reilly
Eileen M. O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary & Neuroendocrine Cancers
Gastrointestinal Oncology Service
Associate Director
David M. Rubenstein Center for Pancreatic Cancer Research
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY


2 Ways to Register
  1. Online: Click here.
  2. Phone: Please call +1-(888)-949-0045 or +1-(609)-378-3701.
Physicians' Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC (PER®) fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please notify us in order to receive service. Please call (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

By attending a PER® conference, meeting or related activity ("Events"), all participants, attendees, exhibitors, sponsors, and guests ("you") create an agreement between you and PER® regarding the use and distribution of your image, including but not limited to your name, voice, and likeness ("Image"). By attending the Events, you acknowledge and agree that photographs, video, and/or audio recordings may be taken of you and you grant permission to PER® (and its agents) to utilize, in perpetuity, your Image in any electronic or print distribution, or by other means hereinafter created, both now and in the future, for any lawful purpose as determined by PER®.

Meeting information is accurate at the time of posting.

PER® complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

In case of onsite emergency:

Professional Information


Calendar of Events
Filter By